ArticleAME case reports2026
SMARCA4-deficient undifferentiated thoracic tumors with rare nasal cavity and gluteal metastases: a case report and literature review.
Article in AME case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: SMARCA4-deficient undifferentiated thoracic tumor (SMARCA4-UT) is an extremely aggressive malignancy that primarily affects the lung and mediastinum. It predominantly occurs in males with a heavy smoking history, and the associated survival typically does not exceed 1 year. Currently, no standard treatment regimen has been established for this disease, and a limited response to conventional chemotherapy has been noted in SMARCA4-UT. Some studies have suggested that multimodal management combining immunotherapy with chemotherapy and local consolidation therapy may offer a certain survival benefit for this disease. Case Description: Here, we report the case of a 73-year-old male with a long history of heavy smoking who was diagnosed with SMARCA4-UT with brain metastasis. The patient exhibited a negative driver gene status and a programmed death ligand-1 (PD-L1) tumor proportion score (TPS) of <1%. During disease progression, he developed rare nasal cavity and gluteal metastases. A multimodal treatment strategy was employed for this patient. Initially, systemic therapy comprising sintilimab plus chemotherapy, along with stereotactic radiosurgery (SRS) for brain metastasis, was administered. This combined approach was followed by consolidation radical radiotherapy for pulmonary lesions, and a partial response (PR) was achieved. Upon disease progression, newly emerging brain, nasal cavity, and gluteal metastases were managed with SRS, surgical resection, and palliative radiotherapy, respectively. The patient ultimately achieved an overall survival (OS) of 27 months. Conclusions: In this case, a comprehensive treatment strategy was implemented, consisting primarily of chemotherapy combined with immunotherapy, along with dynamic and real-time local interventions, such as surgical resection and radiotherapy for residual or oligometastatic lesions. The results indicate that this approach may confer significant survival benefit in patients with SMARCA4-UT with rare nasal cavity and gluteal metastases, irrespective of PD-L1 expression levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.